Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer

by | Dec 24, 2025 | Clinical Trials | 0 comments

​ Conditions: Pancreatic Cancer Non-resectable

Interventions: Drug: Experimental: Tunlametinib+gemcitabine+albumin paclitaxel + cetuximab β

Sponsors: Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting Conditions: Pancreatic Cancer Non-resectable
Interventions: Drug: Experimental: Tunlametinib+gemcitabine+albumin paclitaxel + cetuximab β
Sponsors: Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *